ML264

ML264 is a third-generation **small molecule inhibitor** targeting the transcription factors **KLF5 (Krüppel-like factor 5)** and its upstream regulator **EGR1 (early growth response 1)**. It was developed to inhibit the growth of colorectal cancer cells by suppressing KLF5 expression and function, leading to effects on cell cycle progression (notably S-phase and mitotic blockade) and reduced proliferation. ML264 also affects multiple cancer-associated signaling pathways, including the **RAS/MAPK, PI3K/AKT, and WNT/β-catenin pathways**. It has demonstrated efficacy in preclinical models of **colorectal cancer** (in vivo and in vitro), and recent studies indicate antiproliferative activity in **osteosarcoma** cells via inhibition of **JAK2/STAT3 and WNT/β-catenin signaling**. Developed and initially characterized at The Scripps Research Institute, ML264 remains in preclinical development with no clinical approvals to date[1][3][4].